Breaking News Instant updates and real-time market news.

UMRX

Unum Therapeutics

$1.40

0.07 (5.26%)

, SGEN

Seattle Genetics

$106.85

0.52 (0.49%)

16:07
11/04/19
11/04
16:07
11/04/19
16:07

Unum Therapeutics shifts focus to ACTR, BOXR product candidates

Unum Therapeutics (UMRX) announced a strategic shift to focus development on its ACTR and BOXR product candidates in solid tumors and supportive platform capabilities. ACTR707 was engineered for properties that optimize its function in solid tumors including increased proliferation, cytokine secretion, and persistence. With Unum's focus on developing therapies for solid tumors, the company will de-prioritize investment in its hematologic programs. Testing through the first four dose levels in the ongoing ATTCK-20-03 Phase 1 trial in non-Hodgkin lymphoma has now established proof-of-concept for ACTR707. Given favorable tolerability to date at relatively low doses, Unum is announcing plans to continue limited dose escalation to inform potential future development of the program in 2020. Separately, Unum and its partner, Seattle Genetics (SGEN) have suspended further dose-escalation of the ATTCK-17-01 Phase 1 trial of ACTR087 with SEA-BCMA in multiple myeloma pending a further review of this program. No dose-limiting toxicities, or DLTs, following ACTR087 administration were reported and no severe adverse events of cytokine release syndrome, or CRS, or neurologic events have been observed to date. Phase 1 ATTCK-34-01 Trial: ACTR707 combined with trastuzumab to treat advanced HER2+ solid tumor cancers. Five clinical sites are now activated to support the Phase 1 trial that is currently enrolling patients. Unum expects to report preliminary safety data from patients treated in the first dose cohort of the trial by the end of this year and to report safety and clinical response data from multiple dose cohorts in 2020. BOXR1030: Incorporating the GOT2 transgene and targeting GPC3+ solid tumor cancers. Unum's first product candidate selected from its Bolt-On Chimeric Receptor, or BOXR, platform, BOXR1030, continues to progress towards first-in-human clinical trials. BOXR1030 expresses a glypican-3, or GPC3, targeted chimeric antigen receptor, or CAR, and leverages the "bolt-on" transgene glutamic-oxaloacetic transaminase 2, or GOT2, to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism. Preclinical studies have characterized the mechanism of action of BOXR1030's bolt-on transgene with further details to be presented at the upcoming Society for Immunotherapy of Cancer conference during November 6-10, 2019. Based on recent progress, Unum now plans to file an investigational new drug (IND) application for BOXR1030 in late 2020, enabling subsequent clinical testing in GPC3+ cancers. BOXR Platform Expansion: Unum's BOXR platform was established over two years ago with the aim of discovering novel transgenes that can be co-expressed with chimeric-targeting receptors to improve the function of T cells in the solid tumor microenvironment. As part of its strategic shift to target solid tumors, Unum will be scaling up its BOXR platform capabilities with the objectives of: expanding the scope of biological mechanisms and transgenes in its proprietary BOXR library, enabling BOXR bolt-on applications for a broad range of immune cell therapies, including both autologous and allogeneic approaches and advancing new BOXR product candidates into the clinic. Phase 1 ATTCK-20-03 trial: ACTR707 combined with rituximab for relapsed/refractory non-Hodgkin lymphoma. As a preliminary update provided today for the six patients treated in Cohort 4, complete response was achieved at the first response assessment in two of six patients as of the October analysis, yielding a complete response rate of 40% in Cohorts 1 through 4. Of the eight complete responders, four remained in complete response at six months of follow-up, two remain in complete response but have not yet reached the six-month timepoint for evaluation, and two progressed before the six-month timepoint. In Cohorts 1 through 4, ACTR707 was well-tolerated in combination with rituximab. No DLTs, no adverse events of CRS, and no severe neurological adverse events including neurotoxicity have been reported as of the October 2019 cutoff. Further results will be presented at the American Society for Hematology Annual Meeting. Unum plans to enroll up to two additional cohorts (three to four patients per cohort) in the trial, escalating the maximum dose up to 180M ACTR707+ T cells. With patient screening and planned dosing underway, Unum plans to report preliminary results from this dose escalation during 2020. The ability to differentiate on both efficacy and safety relative to currently available therapies and those in development from these additional cohorts will drive a decision during 2020 whether to advance the program into an expanded dose cohort and potential pivotal studies. Phase 1 ATTCK-17-01 trial: ACTR087 combined with SEA-BCMA for relapsed/refractory multiple myeloma. Two additional cohorts of patients have been treated in the Phase 1 trial in 2019, escalating doses of the SEA-BCMA antibody to 2.0 mg/kg and of the ACTR087+ T cells to 50M. Unum and Seattle Genetics have suspended further dose-escalation of the trial and are reviewing the next steps with this program.

UMRX

Unum Therapeutics

$1.40

0.07 (5.26%)

SGEN

Seattle Genetics

$106.85

0.52 (0.49%)

  • 07

    Dec

  • 15

    Mar

UMRX Unum Therapeutics
$1.40

0.07 (5.26%)

07/03/19
RHCO
07/03/19
NO CHANGE
Target $6
RHCO
Buy
Unum Therapeutics price target lowered to $6 from $10 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on Unum Therapeutics to $6 after yesterday's FDA announcement of a clinical hold on its Phase 1 trial ATTCK-20-2 evaluating ACTR087 in combination with rituximab. The analyst is retaining a Buy rating on the stock however, stating that his discussions with the management indicated the program was already de-prioritized in November of 2018 "in favor of the '707 construct", and the hold should yield a limited read through to other programs.
07/03/19
COWN
07/03/19
NO CHANGE
COWN
Market Perform
Unum Therapeutics clinical hold not an issue, says Cowen
Cowen analyst Yaron Werber noted the FDA placed a clinical hold on ACTR087 adding to ongoing concerns about the potential of its platform given lackluster efficacy data. The analyst said the hold is not an issue as it was deprioritized and the prospects for the stock may lie in the BOXR platform. Werber maintained his Market Perform rating on Unum Therapeutics shares.
07/03/19
HCWC
07/03/19
NO CHANGE
Target $18
HCWC
Buy
Unum Therapeutics shares overreacted to clinical hold, says H.C. Wainwright
Unum Therapeutics shares overreacted yesterday to news of a clinical hold on the Phase 1 trial ATTCK-20-2, which may provide an attractive entry point, H.C. Wainwright analyst Andrew Fein tells investors in a research note. The analyst says that although the clinical hold raises concerns on potential "narrower-than-expected therapeutic window" of ACTR-087 in B-cell malignancies, his comfort in a positive outlook of ATTCK-20-02 and ACTR-T cells in general is derived from the fact that approved CAR-T therapies, Kymriah and Yescarta, are both associated with similar serious adverse events. The analyst reiterates a Buy rain on Unum Therapeutics with an $18 price target ahead of the company's multiple data in 2019.
08/13/19
WEDB
08/13/19
NO CHANGE
Target $13
WEDB
Outperform
Unum Therapeutics price target lowered to $13 from $20 at Wedbush
Wedbush analyst David Nierengarten lowered his price target for Unum Therapeutics to $13 from $20, while reiterating an Outperform rating on the shares. The analyst notes that the company provided a preliminary update from the Phase 1 ATTCK-20-03 trial of ACTR707 + rituximab combo in r/r B-cell non-Hodgkin lymphoma with data from Cohort 3, which had a complete response of 20% and an overall response rate of 80%. Although the analyst acknowledges that it was "encouraging" to see a higher response rate in Cohort 3, the slip in CR rate is "difficult to overlook," given a CR of 50% and 33% in Cohorts 1 and 2, respectively. Nonetheless, Nierengarten sees the data readouts in the second half of 2019 as opportunity to lend credibility to Unum Therapeutics' platform and provide upside to the company's valuation.
SGEN Seattle Genetics
$106.85

0.52 (0.49%)

10/22/19
OPCO
10/22/19
NO CHANGE
Target $110
OPCO
Outperform
Seattle Genetics price target raised to $110 from $92 at Oppenheimer
Oppenheimer analyst Silvan Tuerkcan raised his price target for Seattle Genetics to $110 from $92 after tucatinib, the company's HER2+ targeting oral TKI, hit the primary endpoint of PFS improvement over control with a 46% reduction in the risk of disease progression or death. Tucatinib + trastuzumab + capecitabine also showed an improvement in OS with a 34% risk reduction and superior PFS in patients with brain metastases with a 52% risk reduction, he adds. The analyst views the early OS benefit as extremely positive as well as the brain metastasis outcome following his discussions with an expert at the MD Anderson brain metastasis clinic. Tuerkcan reiterates an Outperform rating on the shares.
10/22/19
RBCM
10/22/19
NO CHANGE
Target $109
RBCM
Outperform
Seattle Genetics price target raised to $109 from $80 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Seattle Genetics to $109 after the "unexpectedly impressive" phase 3 data of its tucatinib drug in patients with HER2-positive breast cancer. The analyst is boosting his breadth and depth forecasts for tucatinib across indications, also raising his market penetration estimates to 75% from 45% and modeling peak risk adjusted sales of $531M and $171M in respective U.S. and EU5 markets. MacKay is keeping his Outperform rating on Seattle Genetics.
10/22/19
LEER
10/22/19
NO CHANGE
Target $120
LEER
Outperform
Seattle Genetics price target raised to $120 from $102 at SVB Leerink
SVB Leerink analyst Andrew Berens raised his price target for Seattle Genetics to $120 from $102 following positive topline data from the pivotal HER2CLIMB trial for tucatinib. The analyst remains bullish on Seattle Genetics as a pipeline driven story, with positive momentum driven by enthusiasm for enfortumab vedotin in bladder cancer following strong data presented at ESMO, tucatinib HER2CLIMB success, which provides the company's first win in small molecules and a catalyst for a global footprint, and increasing confidence in the ADC + I/O synergy story, driving increased fundamental and strategic value for the ADC platform. He reiterates an Outperform rating on the shares.
10/29/19
PIPR
10/29/19
NO CHANGE
Target $120
PIPR
Overweight
Seattle Genetics price target raised to $120 from $95 at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro raised his price target on Seattle Genetics to $120 after its "modest" beat on Adcetris revenue in Q3 along with an upwardly narrowed outlook for FY19. The analyst notes that the company has an "additional opportunity" driven by the potential launch for its Enfortumab vedotin, or EV, in 3rd-line UBC in 2020, along with other opportunities across the pipeline over the near term. Catanzaro also keeps his Overweight rating on Seattle Genetics.

TODAY'S FREE FLY STORIES

EVH

Evolent Health

$8.60

-0.39 (-4.34%)

, ANTM

Anthem

$280.75

-2.84 (-1.00%)

13:48
12/11/19
12/11
13:48
12/11/19
13:48
Periodicals
Outgoing Kentucky administration upholds 'snub' of Evolent partner, LCJ says »

The finance secretary of…

EVH

Evolent Health

$8.60

-0.39 (-4.34%)

ANTM

Anthem

$280.75

-2.84 (-1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAAS

Pan American Silver

$20.30

0.53 (2.68%)

13:45
12/11/19
12/11
13:45
12/11/19
13:45
Options
Pan American Silver call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
12/11/19
12/11
13:45
12/11/19
13:45
General news
Treasury Budget to be reported at 14:00 »

November Treasury Budget…

13:45
12/11/19
12/11
13:45
12/11/19
13:45
General news
FOMC Meeting Announcement Federal Funds Rate to be reported at 14:00 »

FOMC Meeting Announcement…

SBPH

Spring Bank Pharmaceuticals

$3.20

-0.25 (-7.25%)

13:41
12/11/19
12/11
13:41
12/11/19
13:41
Recommendations
Spring Bank Pharmaceuticals analyst commentary  »

Spring Bank to add CASOs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$13.99

-0.155 (-1.10%)

13:25
12/11/19
12/11
13:25
12/11/19
13:25
Options
CenturyLink call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFX

Colfax

$34.68

0.39 (1.14%)

13:25
12/11/19
12/11
13:25
12/11/19
13:25
Conference/Events
Cowen industrial innovation analyst to hold an analyst/industry conference call »

Industrial Innovation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 18

    Dec

BIIB

Biogen

$293.60

-3.45 (-1.16%)

13:25
12/11/19
12/11
13:25
12/11/19
13:25
Conference/Events
SVB Leerink biotech analyst to hold analyst/industry conference call »

Biotech Analysts, along…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

XLNX

Xilinx

$93.24

1.99 (2.18%)

13:25
12/11/19
12/11
13:25
12/11/19
13:25
Conference/Events
Xilinx participates in a conference call with Benchmark »

Semiconductor Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 06

    Jan

  • 28

    Jan

DISCA

Discovery

$32.21

-0.03 (-0.09%)

, DISCK

Discovery Inc.

$29.98

-0.005 (-0.02%)

13:21
12/11/19
12/11
13:21
12/11/19
13:21
Periodicals
Bruin Sports explores sale of streaming provider Deltatre, Bloomberg says »

Bruin Sports Capital is…

DISCA

Discovery

$32.21

-0.03 (-0.09%)

DISCK

Discovery Inc.

$29.98

-0.005 (-0.02%)

DIS

Disney

$146.88

0.76 (0.52%)

AMZN

Amazon.com

$1,737.40

-1.75 (-0.10%)

CMCSA

Comcast

$42.17

-0.6 (-1.40%)

CMCSK

Comcast

$0.00

(0.00%)

TWTR

Twitter

$30.17

0.32 (1.07%)

NFLX

Netflix

$297.28

4.07 (1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

LQDT

Liquidity Services

$6.15

-0.27 (-4.21%)

13:21
12/11/19
12/11
13:21
12/11/19
13:21
Recommendations
Liquidity Services analyst commentary  »

Liquidity Services on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
12/11/19
12/11
13:17
12/11/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
12/11/19
12/11
13:16
12/11/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLW

Corning

$28.28

0.28 (1.00%)

13:15
12/11/19
12/11
13:15
12/11/19
13:15
Options
Corning put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

PNRG

PrimeEnergy

$153.00

-2 (-1.29%)

13:15
12/11/19
12/11
13:15
12/11/19
13:15
Hot Stocks
PrimeEnergy director Clint Hurt sells over $1.1M in company shares »

PrimeEnergy director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMBA

Ambarella

$54.84

2.33 (4.44%)

13:05
12/11/19
12/11
13:05
12/11/19
13:05
Options
Ambarella call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

FB

Facebook

$201.00

0.1 (0.05%)

, ICE

IntercontinentalExchange

$92.63

0.31 (0.34%)

12:56
12/11/19
12/11
12:56
12/11/19
12:56
Periodicals
Nasdaq on track to beat NYSE in IPOs for first time since 2012, WSJ says »

Companies are on pace to…

FB

Facebook

$201.00

0.1 (0.05%)

ICE

IntercontinentalExchange

$92.63

0.31 (0.34%)

NDAQ

Nasdaq

$104.36

-0.26 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 29

    Jan

  • 06

    Feb

12:55
12/11/19
12/11
12:55
12/11/19
12:55
Conference/Events
UBS retail analysts to hold an analyst/industry conference call »

Retail Analysts…

SGEN

Seattle Genetics

$111.78

-2.19 (-1.92%)

12:53
12/11/19
12/11
12:53
12/11/19
12:53
Recommendations
Seattle Genetics analyst commentary  »

Seattle Genetics data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

TWTR

Twitter

$30.16

0.31 (1.04%)

, SQ

Square

$65.52

-0.3 (-0.46%)

12:48
12/11/19
12/11
12:48
12/11/19
12:48
On The Fly
#SocialStocks: YouTube updates harassment policy, Snapchat 'deepfake' GIFs »

Welcome to…

TWTR

Twitter

$30.16

0.31 (1.04%)

SQ

Square

$65.52

-0.3 (-0.46%)

FB

Facebook

$201.03

0.13 (0.06%)

AMZN

Amazon.com

$1,738.68

-0.47 (-0.03%)

SNAP

Snap

$14.15

0.065 (0.46%)

GOOGL

Alphabet Class A

$1,342.74

-0.3 (-0.02%)

GOOG

Alphabet

$1,344.23

-0.27 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 26

    Feb

CIEN

Ciena

$35.15

0.45 (1.30%)

, LOVE

Lovesac

$14.52

0.08 (0.55%)

12:48
12/11/19
12/11
12:48
12/11/19
12:48
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CIEN

Ciena

$35.15

0.45 (1.30%)

LOVE

Lovesac

$14.52

0.08 (0.55%)

VERU

Veru

$2.27

-0.03 (-1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 17

    Dec

  • 19

    Dec

LULU

Lululemon

$232.23

2.67 (1.16%)

, NDSN

Nordson

$165.56

-0.19 (-0.11%)

12:48
12/11/19
12/11
12:48
12/11/19
12:48
Earnings
Notable companies reporting after market close »

Notable companies…

LULU

Lululemon

$232.23

2.67 (1.16%)

NDSN

Nordson

$165.56

-0.19 (-0.11%)

OXM

Oxford Industries

$74.50

-1.46 (-1.92%)

MESA

Mesa Air

$9.04

-0.04 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

CSCO

Cisco

$44.29

0.18 (0.41%)

, CMCSA

Comcast

$42.04

-0.73 (-1.71%)

12:45
12/11/19
12/11
12:45
12/11/19
12:45
Hot Stocks
Cisco announces 'Internet for the Future' strategy »

Cisco (CSCO) unveiled…

CSCO

Cisco

$44.29

0.18 (0.41%)

CMCSA

Comcast

$42.04

-0.73 (-1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 08

    Jan

  • 12

    Feb

ADI

Analog Devices

$115.90

1.48 (1.29%)

12:45
12/11/19
12/11
12:45
12/11/19
12:45
Options
Analog Devices call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$313.73

0.18 (0.06%)

12:45
12/11/19
12/11
12:45
12/11/19
12:45
Hot Stocks
Gundlach says in next recession, U.S. will be worst stock market in world »

DoubleLine CEO Jeffrey…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$313.73

0.18 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.